350 mg leronlimab

Drug identity checked against registry records

Also recorded as PRO 140

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenNCT06699836CytoDyn, Inc.Phase 2Active not recruiting2028-01Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.